Browsing: Dizal Pharmaceutical

SHANGHAI, Dec. 12, 2023 /PRNewswire/ — Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th…

Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART…

SHANGHAI, Sept. 14, 2023 /PRNewswire/ — Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical…